Can Nuclear DNA Mutations Be Used for Cancer Diagnosis and Treatment?
Yes, specific mutations in nuclear DNA can serve as biomarkers for cancer diagnosis and prognosis. For example, the presence of specific KRAS mutations can indicate a poor prognosis in colorectal cancer. Moreover, targeted therapies designed to inhibit the activity of mutated proteins, such as tyrosine kinase inhibitors for EGFR mutations in lung cancer, have shown significant clinical benefits.
